Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL8660527 | 1.00 | MAOA (0.46) | MAOAMAOBCYP1A2ADRA2AADRA2B | |
| Oxalic Acid SCHEMBL7347213 | 1.00 | MAOA (0.46) | MAOAMAOBCYP1A2ADRA2AADRA2B | |
| SCHEMBL5006591 | 0.88 | — | — | |
| SCHEMBL219075 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL5618345 | 0.86 | MAOB (0.52) | MAOAMAOBCYP1A2ADRA2AADRA2B | |
| Oxalic Acid SCHEMBL7351754 | 0.82 | MAOB (0.43) | MAOAMAOBCYP1A2ADRA2AADRA2B | |
| Oxalic Acid SCHEMBL7344407 | 0.81 | KDM4E (0.33) | MAOAMAOBCYP1A2ADRA2AADRA2B | |
| SCHEMBL29950583 | 0.74 | MAOB (0.42) | MAOAMAOBCYP1A2ADRA2AADRA2B | |
| SCHEMBL220924 | 0.71 | MAOA (0.47) | MAOAMAOBCYP1A2ADRA2AADRA2B | |
| SCHEMBL22450024 | 0.69 | MAOA (0.46) | MAOAMAOBCYP1A2ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| EP-0573498-B1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIV SASKATCHEWAN (CA) | 1998-11-18 | — | — | EP | claimed |
| EP-0573498-A1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1993-12-15 | — | — | EP | claimed |
| WO-1992015551-A1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1992-09-17 | — | — | WO | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-0573498-B1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIV SASKATCHEWAN (CA) | 1998-11-18 | — | — | EP | disclosed |
| US-5508311-A | Aliphatic propargylamines as selective MAO-B inhibitors and as neuroprotective agents | UNIVERSITY OF SASKATCHEWAN (CA) | 1996-04-16 | — | — | US | disclosed |
| EP-0573498-A1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992015551-A1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOA 2/4885MAOB 1/4885CYP1A2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.